Literature DB >> 17391127

The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection.

J E Locke1, A A Zachary, M Haas, J K Melancon, D S Warren, C E Simpkins, D L Segev, R A Montgomery.   

Abstract

Antibody-mediated rejection (AMR) after desensitization for a positive crossmatch (+XM) live donor renal transplant can be severe and result in sudden onset oliguria and loss of the allograft. Attempts to rescue these kidneys using plasmapheresis (PP) and IVIg may be ineffective due to the magnitude of antibody burden that must be controlled to prevent renal thrombosis or cortical necrosis. We review our experience using splenectomy combined with PP/IVIg as rescue therapy for patients experiencing an acute deterioration in renal function and a rise in donor-specific antibody within the first posttransplant week after desensitization for a +XM. Five patients underwent immediate splenectomy followed by PP/IVIg and had return of allograft function within 48 h of the procedure. Emergent splenectomy followed by PP/IVIg may be an effective treatment for reversing severe AMR.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17391127     DOI: 10.1111/j.1600-6143.2006.01709.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  24 in total

1.  Treatment of Late Class II Antibody-Mediated Rejection Status Postkidney Transplantation: Two Case Reports.

Authors:  Eric Siskind; Madhu Bhaskaran; Fouad Boctor; Kavin Shah; Ernesto Molmenti
Journal:  Int J Angiol       Date:  2012-06

Review 2.  Current state of renal transplant immunosuppression: Present and future.

Authors:  Hari Varun Kalluri; Karen L Hardinger
Journal:  World J Transplant       Date:  2012-08-24

3.  The spleen is the major source of antidonor antibody-secreting cells in murine heart allograft recipients.

Authors:  A Sicard; T W Phares; H Yu; R Fan; W M Baldwin; R L Fairchild; A Valujskikh
Journal:  Am J Transplant       Date:  2012-03-15       Impact factor: 8.086

Review 4.  Antibody-mediated rejection in pediatric kidney transplantation: pathophysiology, diagnosis, and management.

Authors:  Yolanda W Ng; Manpreet Singh; Minnie M Sarwal
Journal:  Drugs       Date:  2015-04       Impact factor: 9.546

5.  Long-term outcomes of eculizumab-treated positive crossmatch recipients: Allograft survival, histologic findings, and natural history of the donor-specific antibodies.

Authors:  Carrie A Schinstock; Andrew J Bentall; Byron H Smith; Lynn D Cornell; Matthew Everly; Manish J Gandhi; Mark D Stegall
Journal:  Am J Transplant       Date:  2018-12-15       Impact factor: 8.086

Review 6.  Novel immunosuppressive agents in kidney transplantation.

Authors:  Karen L Hardinger; Daniel C Brennan
Journal:  World J Transplant       Date:  2013-12-24

7.  Outcomes of ABO-incompatible kidney transplantation in the United States.

Authors:  John R Montgomery; Jonathan C Berger; Daniel S Warren; Nathan T James; Robert A Montgomery; Dorry L Segev
Journal:  Transplantation       Date:  2012-03-27       Impact factor: 4.939

Review 8.  Incompatible kidney transplantation: lessons from a decade of desensitization and paired kidney exchange.

Authors:  Daniel S Warren; Robert A Montgomery
Journal:  Immunol Res       Date:  2010-07       Impact factor: 2.829

9.  Acute Antibody-Mediated Rejection in Renal Transplantation: Current Clinical Management.

Authors:  Carrie Schinstock; Mark D Stegall
Journal:  Curr Transplant Rep       Date:  2014-03-13

Review 10.  Role of secondary lymphoid tissues in primary and memory T-cell responses to a transplanted organ.

Authors:  Yue-Harn Ng; Geetha Chalasani
Journal:  Transplant Rev (Orlando)       Date:  2009-10-20       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.